Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 7/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.31 |
| ▸ | JUN | P05412 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | BUB1 | O43683 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3684122 | 0.82 | POLB (0.41) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL3672992 | 0.82 | MAPT (0.40) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3675236 | 0.78 | GAA (0.47) | — | |
| SCHEMBL3678655 | 0.78 | CA12 (0.41) | — | |
| SCHEMBL3677491 | 0.76 | ALDH1A1 (0.46) | KDR | |
| SCHEMBL3682116 | 0.75 | ALDH1A1 (0.47) | — | |
| SCHEMBL3678858 | 0.75 | HSD17B10 (0.44) | KDRELANE | |
| SCHEMBL3684358 | 0.74 | NPC1 (0.42) | — | |
| SCHEMBL3684385 | 0.74 | NPC1 (0.42) | — | |
| SCHEMBL828580 | 0.73 | EGFR (0.41) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741514-B2 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20060281629-A1 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | ISHII YASUTAKA | 2006-12-14 | — | — | US | disclosed |
| US-7115541-B2 | Catalyst comprising n-substituted cyclic imides and processes for preparing organic compounds with the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-10-03 | — | — | US | disclosed |
| EP-1338336-A1 | CATALYSTS COMPRISING N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS | Daicel Chemical Industries, Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-20030013603-A1 | Catalyst comprising n-substituted cylic imides and processes for preparing organic compounds with the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281629-A1 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | NOS2, NOS1, NOS3 | GABRA1 334/4885GABRG2 635/4885GABRB3 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.